Thomas Powles
About
Thomas Powles is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology.
According to data from OpenAlex, Thomas Powles has authored 105 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Pulmonary and Respiratory Medicine, 55 papers in Surgery and 51 papers in Oncology. Recurrent topics in Thomas Powles's work include Bladder and Urothelial Cancer Treatments (49 papers), Renal cell carcinoma treatment (46 papers) and Cancer Immunotherapy and Biomarkers (41 papers). Thomas Powles is often cited by papers focused on Bladder and Urothelial Cancer Treatments (49 papers), Renal cell carcinoma treatment (46 papers) and Cancer Immunotherapy and Biomarkers (41 papers). Thomas Powles collaborates with scholars based in United Kingdom, United States and France. Thomas Powles's co-authors include Noah M. Hahn, Joaquim Bellmunt, Peter H. O’Donnell, Dean F. Bajorin, Daniel Castellano, Petros Grivas, Arjun Vasant Balar, Rodolfo F. Perini, Mary J. Savage and Ronald de Wit and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer.
In The Last Decade
Thomas Powles
97 papers receiving 3.6k citations
Hit Papers
Peers
Thomas Powles
Christian Poehlein United States
Bradley A. McGregor United States
Lisa Sengeløv Denmark
Rodolfo F. Perini United States
Daniel A. Vaena United States
André P. Fay United States
Jacqueline Vuky United States
Alexandre Lambert United States
Suba Krishnan United States
Saby George United States
Citations per year, relative to Thomas Powles Thomas Powles (= 1×)
peers
Christian Poehlein
Countries citing papers authored by Thomas Powles
Since
Specialization
Citations
This map shows the geographic impact of Thomas Powles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Powles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Powles more than expected).
Fields of papers citing papers by Thomas Powles
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas Powles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Powles. The network helps show where Thomas Powles may publish in the future.
Co-authorship network of co-authors of Thomas Powles
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Powles. A scholar is included among the top collaborators of Thomas Powles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Powles. Thomas Powles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gao, Xin, Amita Patnaik, Nehal J. Lakhani, et al.. (2025). NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.. Journal of Clinical Oncology. 43(5_suppl).
2.
Pal, Sumanta K., Thomas Powles, Ravindran Kanesvaran, et al.. (2025). STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma. Future Oncology. 21(7). 787–794.
3.
Necchi, Andrea, Félix Guerrero‐Ramos, Paul L. Crispen, et al.. (2025). TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial. The Lancet Oncology. 26(10). 1312–1322.
4.
Powles, Thomas, Mauricio Burotto, Bernard Escudier, et al.. (2024). Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open. 9(5). 102994–102994.
5.
Powles, Thomas, Tibor Csőszi, Yohann Loriot, et al.. (2024). Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study. Clinical Genitourinary Cancer. 23(1). 102261–102261.
6.
Powles, Thomas, Joaquim Bellmunt, Éva Compérat, et al.. (2024). ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Annals of Oncology. 35(6). 485–490.
7.
Sweeney, Christopher, Ryon P. Graf, David Fabrizio, et al.. (2023). Circulating tumor DNA analysis of IMbassador250: Association of ctDNA fraction, AR alterations and therapy outcome in mCRPC.. Journal of Clinical Oncology. 41(6_suppl). LBA249–LBA249.
8.
Takemura, Kosuke, Naveen S. Basappa, Bernadett Szabados, et al.. (2023). Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology. 41(6_suppl). 600–600.
9.
Sherman, Eric J., Philip R. Debruyne, Bhumsuk Keam, et al.. (2023). Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study. ESMO Open. 8(2). 100877–100877.
10.
Watts, Isabella, Kenrick Ng, Rami Mustapha, et al.. (2023). Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer. Oncology and Therapy. 11(1). 49–64.
11.
Chalabi, Myriam, Andrés F. Cardona, Deepti R. Nagarkar, et al.. (2020). Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Annals of Oncology. 31(4). 525–531.
12.
Al‐Lamki, Rafia S., Nicholas J. Hudson, John R. Bradley, et al.. (2020). The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro. Biology. 9(4). 74–74.
13.
Powles, Thomas, Joshua J. Meeks, Matt D. Galsky, et al.. (2019). A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).. Journal of Clinical Oncology. 37(15_suppl). TPS4592–TPS4592.
14.
Escudier, Bernard, Thomas Powles, Robert J. Motzer, et al.. (2018). Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Journal of Clinical Oncology. 36(8). 765–772.
15.
Dijk, Nick van, Samuel A. Funt, Christian U. Blank, et al.. (2018). The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. European Urology. 75(3). 435–444.
16.
Necchi, Andrea, Gregory R. Pond, Sumanta K. Pal, et al.. (2017). Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clinical Genitourinary Cancer. 16(2). e483–e490.
17.
Stewart, Grant D., Maria De Santis, Bernard Escudier, Thomas Powles, & Guru Sonpavde. (2016). Immunotherapy for Renal Cancer: Sequencing and Combinations. European Urology Focus. 2(6). 582–588.
18.
Meeks, Joshua J., Joaquim Bellmunt, Bernard H. Bochner, et al.. (2012). A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology. 62(3). 523–533.
19.
Gerlinger, Marco, Peter Wilson, Thomas Powles, & Jonathan Shamash. (2010). Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapy. European Journal of Cancer. 46(16). 2913–2918.
20.
Sonpavde, Guru, Kim N., Thomas Powles, et al.. (2007). Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 110(12). 2628–2639.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Christian Poehlein Breakdown of academic impact, for papers by Bradley A. McGregor Breakdown of academic impact, for papers by Lisa Sengeløv Breakdown of academic impact, for papers by Rodolfo F. Perini Breakdown of academic impact, for papers by Daniel A. Vaena Breakdown of academic impact, for papers by André P. Fay Breakdown of academic impact, for papers by Jacqueline Vuky Breakdown of academic impact, for papers by Alexandre Lambert Breakdown of academic impact, for papers by Suba Krishnan Breakdown of academic impact, for papers by Saby George